The feasibility of airways hyperresponsiveness as an inclusion criterion for studies on childhood asthma.
The feasibility of moderately severe airway hyperresponsiveness (AH) was examined as an inclusion criterion for clinical trials in asthmatic children. During the baseline period of a long-term clinical trial in asthmatic children, maintenance therapy with fluticasone (200 microg x day(-1)) was stopped for a maximum of 8 weeks and methacholine challenges were performed at 2-week intervals or earlier if the patients' condition deteriorated. Patients were eligible to continue the study if the provocative dose of methacholine causing a 20% fall in forced expired volume in one second (FEV1) (PD20) was <80 microg. Fifty-one per cent of the children did not develop a PD20 < 80 microg after withdrawal of fluticasone. Patients with or without a PD20 <80 microg did not differ in duration of asthma, duration of treatment, or peak flow variation. Patients with a PD20 <80 microg had higher levels of total and specific immunoglobulin-E, and lower levels of FEV1 and mean maximal expiratory flow than patients with a PD20 > or = 80 microg. Forty-four per cent of the patients with a PD20 > or = 80 microg did not have any symptoms during the wash-out period and 39% of these patients remained free from symptoms during one year follow-up. The results of this study suggest that recruiting asthmatic children for clinical trials may be difficult if airways hyperresponsiveness is used as the sole inclusion criterion.
Kamps
A W
AW
Dept of Pediatrics, Isala Klinieken/Weezenlanden Hospital, Zwolle, The Netherlands.
Visser
M J
MJ
de Vries
T W
TW
van Aalderen
W M
WM
Postma
D S
DS
Brand
P L
PL
D000730:Androstadienes / Q000008:administration & dosage / Q000009:adverse effects; D001249:Asthma / Q000175:diagnosis / Q000188:drug therapy*; D016535:Bronchial Hyperreactivity / Q000175:diagnosis / Q000188:drug therapy*; D001985:Bronchial Provocation Tests; D002648:Child; D002986:Clinical Trials as Topic; D005240:Feasibility Studies; D005260:Female; D000068298:Fluticasone; D006801:Humans; D008134:Long-Term Care; D008297:Male; D016210:Methacholine Chloride; D018579:Patient Selection; D013375:Substance Withdrawal Syndrome / Q000175:diagnosis
D000730:Androstadienes; D016210:Methacholine Chloride; D000068298:Fluticasone